Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Esperion Therapeutics, Inc. (ESPR : NSDQ)

• Company Description    Esperion Therapeutics, Inc. is a pharmaceutical company focused on the development of oral lipid-management treatments for cardiovascular diseases caused by elevated levels of LDL-C (bad cholesterol). Number of Employees: 304

• Price / Volume Information    Yesterday's Closing Price: $2.84 Daily Weekly Monthly 20 Day Moving Average: 5,845,707 shares Shares Outstanding: 201.62 (millions) Market Capitalization: $572.61 (millions) Beta: 0.89 52 Week High: $3.94 52 Week Low: $0.69 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 37.20% 34.79% 12 Week 158.18% 134.52% Year To Date 29.09% 13.23%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3891 RANCHERO DRIVE SUITE 150 - ANN ARBOR,MI 48108 USA ph: 734-887-3903 fax: - investorrelations@esperion.com http://www.esperion.com

• General Corporate Information    Officers Sheldon L. Koenig - President; Chief Executive Officer and Director Benjamin Halladay - Chief Financial Officer J. Martin Carroll - Director Seth H.Z. Fischer - Director Alan Fuhrman - Director Peer Information Esperion Therapeutics, Inc. (GSAC) Esperion Therapeutics, Inc. (CASI) Esperion Therapeutics, Inc. (ALCD.) Esperion Therapeutics, Inc. (OMNN) Esperion Therapeutics, Inc. (CGPI.) Esperion Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 29664W105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 201.62 Most Recent Split Date: (:1) Beta: 0.89 Market Capitalization: $572.61 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.06 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.01 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 3.71% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: 236.67 Trailing 12 Months: - PEG Ratio: 63.79 Price Ratios Price/Book: - Price/Cash Flow: 118.21 Price / Sales: 2.14 EPS Growth vs. Year Ago Period: 60.00% vs. Previous Quarter: 90.48% Sales Growth vs. Year Ago Period: 11.58% vs. Previous Quarter: 26.76% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - -0.91 ROA 06/30/25 - -28.41 03/31/25 - -29.47 12/31/24 - 0.92 Current Ratio 06/30/25 - 1.15 03/31/25 - 1.18 12/31/24 - 1.37 Quick Ratio 06/30/25 - 0.76 03/31/25 - 0.81 12/31/24 - 0.99 Operating Margin 06/30/25 - -35.21 03/31/25 - -37.87 12/31/24 - 0.95 Net Margin 06/30/25 - -35.84 03/31/25 - -59.03 12/31/24 - -15.57 Pre-Tax Margin 06/30/25 - -38.80 03/31/25 - -59.03 12/31/24 - -15.57 Book Value 06/30/25 - -2.19 03/31/25 - -2.15 12/31/24 - -1.97 Inventory Turnover 06/30/25 - 1.06 03/31/25 - 1.01 12/31/24 - 0.83 Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©